Pfizer: Zipline, Pfizer And BioNTech Collaboration Paves The Way For Automated, On-Demand Delivery Of First MRNA COVID-19 Vaccines In Ghana

Zipline, the global leader in instant logistics, Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that Zipline has successfully completed the first long-range drone delivery of both authorized mRNA COVID-19 vaccines requiring ultra-cold-chain in Ghana. The collaboration of the companies, which worked together earlier this year to develop and test an end-to-end vaccine delivery solution, will allow for the distribution of approximately 50,000 doses of the Pfizer-BioNTech COVID-19 Vaccine in Ghana, pioneering a new model for vaccine distribution.

In addition to financial support for the pilot program, Pfizer and BioNTech provided technical assistance and know-how specific to the management and storage of the Pfizer-BioNTech COVID-19 Vaccine at -90°C to -60°C. This partnership has paved the way for drone deliveries of all mRNA vaccines.

The companies share a goal to help ensure the safe and equitable distribution of COVID-19 vaccines. Pfizer and BioNTech have committed two billion doses of their COVID-19 vaccine to low- and middle-income countries through 2022 and are actively working on collaborating with both public and private organizations to accelerate the vaccine rollout worldwide. To date, the Pfizer-BioNTech COVID-19 Vaccine has reached 155 countries and territories in every region of the world, including through its agreement with COVAX.

To-date, more than 220,000 COVID-19 vaccine doses from multiple manufacturers have been successfully distributed across Ghana by Zipline, the first company to do so through an autonomous aircraft at national scale. Zipline plans to distribute millions more as supply becomes available. Through this partnership, Pfizer, BioNTech and Zipline have brought together their expertise and capabilities to help advance more equitable vaccine distribution.

“Delivery to people in remote and hard-to-reach places is a primary challenge for global vaccination,” said Keller Rinaudo, Co-founder and CEO, Zipline. “In partnership with Pfizer and BioNTech, we have created a solution to address this potential pain point head on. Together, we are working to help transform vaccine distribution into a more effective, equitable process.”

Making COVID-19 vaccines accessible to an entire country’s population presents logistical challenges for many governments and healthcare organizations, particularly in low- and middle-income countries. Zipline is helping to address these challenges by implementing an end-to-end distribution model that safely delivers any COVID-19 vaccine to all corners of a country through its autonomous aircraft.

“Pfizer has a history of investing with partners to improve access to medicines and vaccines in the most remote areas of the world,” said Caroline Roan, Chief Sustainability Officer, Senior Vice President, Global Health and Social Impact, Pfizer Inc. “We are proud of this collaboration with Zipline to implement breakthrough solutions that help advance equitable access to COVID-19 vaccines, particularly for hard to reach and underserved populations.”

“The global distribution of COVID-19 vaccines requires a coordinated effort. We are working together with local partners and governments to establish a robust local end-to-end manufacturing and distribution network,” said Sierk Poetting, Ph.D., Chief Operating Officer, BioNTech. “This collaboration between Pfizer, BioNTech and Zipline showcases our collective commitment to pioneering new solutions that can help address COVID-19 vaccine access challenges.”

Comments are closed.